Loading...
Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model
BACKGROUND: L-BLP25 antigen-specific cancer immunotherapeutic agent is currently in phase III clinical trials for non-small cell lung cancer. Using a novel human MUC1 transgenic (hMUC1.Tg) lung cancer mouse model, we evaluated effects of L-BLP25 combined with low-dose cyclophosphamide (CPA) pretreat...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2013
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3605365/ https://ncbi.nlm.nih.gov/pubmed/23496860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-64 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|